Neuroscience
Expertise: Neuroscience 40 results
Neuroscience
AAIC
Psychedelic drug development is moving into a more consequential phase. Compounds such as MDMA, psilocybin, LSD, and other psychoactive agents continue to be explored for serious mental health conditions, including post-traumatic stress disorder, treatment-resistant depression, major depressive disorder, and substance...
Neuroscience
3 Shifts Reshaping Alzheimer’s Trial Execution
Learn how evolving FDA programs, modern trial designs, and patient-centered practices are reshaping rare disease development.
Parkinson’s disease is one of the fastest-growing neurological disorders worldwide, supported by a robust and diverse clinical research pipeline. As understanding of disease biology continues to advance, there is growing recognition that traditional trial designs and endpoints may not fully...
Parkinson’s disease (PD) affects an estimated 10 million people worldwide, including more than 1.1 million in the United States. With prevalence rising as the population ages, experts warn of a growing public health crisis and an economic burden that exceeds...
Neuroscience
Raising the Bar in Global MDD Research
Neuroscience
Jennifer Stewart
In CNS trials, inconsistent endpoint assessments can jeopardize outcomes. Premier Research offers customized rater training to reduce variability, minimize placebo response, and improve data quality from the start. Powered by our Remarque™ platform, we deliver real-time monitoring, centralized scoring, and...
The Alzheimer’s research landscape is undergoing a fundamental transformation. With disease-modifying therapies now a reality, sponsors must rethink how they design, recruit for, and execute trials—particularly in early-stage and preclinical populations. This guide explores five strategic imperatives that can help...